ANZCTR search results

The first aim of CAPTIVE is to determine in a randomised double-blind, placebo-controlled trial whether two years treatment with intramuscular testosterone undecanoate is non-inferior to placebo in its effect on non-calcified coronary plaque burden. The second aim is to determine whether testosterone treatment is superior to placebo in slowing progression of coronary atherosclerosis. This study will be conducted in 558 men aged 50-74 years with central adiposity (waist 95 cm or more) and low-normal baseline testosterone (14 nmol/L or less). The primary outcome will be normalised non-calcified coronary plaque volume as measured on computed tomography coronary angiography (CTCA) at baseline and 2 years, with secondary outcomes of high risk plaque characteristics and pericoronary adipose tissue attenuation.

In this study, we will randomly assign 80 people living with dementia into two groups, an intervention or a control group. Forty participants in the intervention group will receive a range of low cost, adaptable, user-centric technologies installed in their homes, while 40 participants in the control group will continue to receive usual care. These technologies include a wearable falls detector, a communication tablet, personalised reminders for medication taking and other routine activities, and motion sensors installed around the home. The study aims to see whether these technologies will help people living with dementia better manage their routine activities of daily living, and examine the impact of these technologies on the people living with dementia and their informal carers. The intervention will be provided for six months.

This project will recruit young adults (18-25 years) to a social media intervention that aims to improve calcium intake of young adults. Our previous research indicates most fail to meet the recommended dietary intake. The CAN-DO (CAlcium Nutrition- Dietary Opportunities) study will have three arms, one intervention group will be exposed to Facebook; one will be exposed to Facebook with text messages groups while the control group will be emailed once with an e-leaflet. Participants will be asked to complete a baseline and end of intervention questionnaire to assess change in dietary calcium intake.

This study aims to evaluate the feasibility of Virtual Surgery School (VSS) for patients scheduled to undergo major abdominal cancer surgery. Who is it for? You may be eligible to join this study if you are aged 18 years or above and are scheduled to undergo upper gastrointestinal surgery (including oesophagectomy), lower gastrointestinal surgery (including pelvic exenteration) or major sarcoma procedures of at least 120 minutes duration at the Peter MacCallum Cancer Centre. Study details: Participants in this study will be allocated to one of two groups based on individual participant preference. One group will participate in our established, well-received hospital based 'Surgery School'. The other will participant in Virtual Surgery School (VSS) using a live Webinar platform, which they can access, anywhere there is an internet connection (e.g. home/community centre). Patients who choose not to participate will receive standard care comprising of general information incorporated into routine care pre-anaesthetic clinic appointments. Surgery School is a pre-operative education pack which includes six information modules; Introduction to Surgery School, aCOUGH, Nausea and pain management, Nutrition, Exercise and Psychological Prehabilitation. These are delivered by presenters from our multidisciplinary team (Physiotherapist, Anaesthetist, Pain Nurse, Psychologist) either in person or via live webinar. It is hoped that the virtual method of assessing Surgery School will reduced inequities to this proven prevention initiative for patients who are unable to attend the hospital.

This is a double blinded randomized trial of Botox injection for the treatment of complex anal fistulae. All patients will have a Seton drain placed at their initial surgery. After six weeks they will be randomized to either Botox injection to the anal sphincter or placebo as well as (in both groups) removal of the Seton drain. Patients will be followed up at 3,12 and 24 weeks to assess healing of the fistula.

Background: Symptoms of anxiety and depression are highly prevalent among people with severe asthma. Despite this, symptoms of anxiety and depression are not frequently assessed in severe asthma management. Due to the high burden and potential under treatment, further investigation is warranted. Aims: o To determine the illness burden of patients with severe asthma and anxiety and depression using patient reported outcome measures o To inform the development of a targeted non-pharmacological intervention for anxiety and depression in a severe asthma population. o To capture emotions and explore the intimate and individual experience of living with severe asthma, anxiety and/or depression through art-based methods.

Gastrointestinal problems in the lower gastrointestinal tract can manifest as irritable bowel symptoms. The Broth & Co Beef Bone Broth Powder contains a nutrient rich mix of amino acids, minerals, collagen, glucosamine and chondroitin, which have been shown to be beneficial for the gastrointestinal system. In this pilot single-arm pre-post study of 12 weeks duration we aim to investigate the effect of the Broth&Co Beef Bone Broth Powder on gastrointestinal disturbances in Australian adults.

Embryo transfer is the final process in the highly technical treatment of IVF. It is performed via the cervix and the embryo is placed into the uterine cavity via a fine catheter. Studies demonstrate that pregnancy rates are better when embryo transfer is performed under ultrasound guidance. Studies have also looked at the position of the bubble(fluid containing the embryo) on ultrasound following embryo transfer, with a sweet spot at 15mm from the fundal endometrium. Currently in most clinics ultrasound guidance is not performed by a person formally trained in pelvic ultrasound. The ultrasound probe is often positioned by the doctor and held by the patient whilst the doctor performs the transfer. The researchers hypothesize that performing the transfer with a trained sonographer will lead to a higher number of embryos being in the best position in the uterine cavity. We hypothesize that as compared to a patient holding the ultrasound probe, the sonographer is skilled at locating the endometrium, dynamically adjusting the probe and guiding the doctor to place the embryo in the ideal position. This study will assess the distance of the bubble from the fundal endometrium immediately following embryo transfer.

This study aims to evaluate biomarkers from blood, tissue, urine, and stool, in order to assess how useful they are in predicting treatment response and side effects from Immunotherapy. Who is it for? You may be eligible to join this study if you are aged 18 years or older and have been diagnosed with non-small cell lung cancer, bladder cancer, or kidney cancer, for which you will be commencing Immunotherapy. Study details This study will involve a taking a variety of biological samples including, blood, urine, stool and tissue on seven separate occasions throughout the 12 month study period. The samples will be used to evaluate new tests (biomarkers) to assess how useful they are in predicting cancer outcomes. It is hoped that these biomarker tests can provide insight to changes in tumour tissue, blood, stool and urine during treatment. The information from this study will be crucial in personalizing Immunotherapy treatment.

Optimal outcomes in total hip arthroplasty are dependent on appropriate component placement, with technological advances providing a platform for guiding component placement to reduce the risk of malpositioned components during surgery. This study will validate the accuracy of the data captured using a handheld imageless navigation system (for total hip arthroplasty) against pre/postoperative CT scans. Patients are to be recruited and data captured as part of the existing approved protocol for John Ireland's patient registry [ACTRN12618000317291].